CTIM-76's 29% ORR in chemo-resistant ovarian cancer is the only human proof on the table — whether dosing optimization converts that signal into a registrational path decides the thesis

Bull

A positive outcome would be Q3W dosing maintaining or exceeding the 29% ORR and 57% DCR seen at target doses under QW, while reducing cytokine release syndrome and improving tolerability through on/off T cell cycling — demonstrating a differentiated, manageable profile. This would validate the dosing optimization hypothesis, support dose selection for an expansion cohort, and give the FDA Fast Track-designated program a credible path toward a registrational design in platinum-resistant ovarian cancer.

Bear

The most likely failure modes are a loss of efficacy signal when switching to Q3W — where less frequent dosing reduces sustained T cell engagement and responses fall below the 29% benchmark — or an unexpected toxicity profile that complicates schedule optimization further. Even if efficacy is preserved, inconclusive data from a small evaluable patient cohort could leave dose selection ambiguous and delay any registrational decision indefinitely.